Early Warning Press Release in Accordance with National Instrument 62-103

Early Warning Press Release in Accordance with National Instrument 62-103

Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 102,500 common shares (each a "Common Share") of Optimi Health Corp. (the "Issuer") at a price of $0.32 in the public market.

Prior to giving effect to the foregoing acquisition of Common Shares, the Acquiror owned and/or had control over an aggregate of 12,583,938 Common Shares, representing approximately 13.02% of the issued and outstanding Common Shares of the Issuer on an undiluted basis. Following completion of the acquisition of the Common Shares, the Acquiror owns or has control or direction over, directly or indirectly, 12.686.438 Common Shares, 533,333 warrants, and 350,000 stock options, representing approximately 13.13% of the issued and outstanding Common Shares of the Issuer on an undiluted basis and approximately 13.91% of the total issued and outstanding Common Shares of the Issuer on a partially diluted basis.

The Acquiror may acquire additional securities or dispose of securities of the Issuer in the future either on the open market, privately or otherwise depending on market conditions, reformulation of plans, other available investment business opportunities and/or other relevant factors.

For further information or to receive a copy of the early warning report filed by the Acquiror with securities regulatory authorities in Canada in connection with this press release, please contact Leah Hodges at (604) 377-0403 or refer to the Issuer's SEDAR+ profile at www.sedarplus.ca.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281095

News Provided by TMX Newsfile via QuoteMedia

OPTI:CC
The Conversation (0)
Optimi Health

Optimi Health

Natural Psychedelic Wellness Alternatives Capitalizing Diverse Revenue Streams

Natural Psychedelic Wellness Alternatives Capitalizing Diverse Revenue Streams Keep Reading...
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors

Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / lobe sciences ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, today... Keep Reading...
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / lobe sciences ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported... Keep Reading...
Solvonis Therapeutics

U.S. Patent allowance received for PTSD discovery programme

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces that it has received a Notice of Allowance (the "Allowance") from the United States Patent and Trademark Office ("USPTO")... Keep Reading...
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / lobe sciences ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Change of auditorsOn October 10,... Keep Reading...
Numinus Wellness Announces Change of Auditor

Numinus Wellness Announces Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as... Keep Reading...

Interactive Chart

Latest Press Releases

Related News